Share Name Share Symbol Market Type Share ISIN Share Description
Avacta LSE:AVCT London Ordinary Share GB00BYYW9G87 ORD 10P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  +0.00p +0.00% 63.00p 62.00p 64.00p 63.00p 62.50p 62.50p 23,847.00 09:54:43
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 2.2 -5.6 -6.9 - 43.08

Avacta (AVCT) Latest News

More Avacta News
Avacta Takeover Rumours

Avacta (AVCT) Share Charts

1 Year Avacta Chart

1 Year Avacta Chart

1 Month Avacta Chart

1 Month Avacta Chart

Intraday Avacta Chart

Intraday Avacta Chart

Avacta (AVCT) Discussions and Chat

Avacta (AVCT) Most Recent Trades

No Trades
Trade Time Trade Price Trade Size Trade Value Trade Type
View all Avacta trades in real-time

Avacta (AVCT) Top Chat Posts

DateSubject
25/3/2017
08:20
Avacta Daily Update: Avacta is listed in the Pharmaceuticals & Biotechnology sector of the London Stock Exchange with ticker AVCT. The last closing price for Avacta was 63p.
Avacta has a 4 week average price of - and a 12 week average price of -.
The 1 year high share price is - while the 1 year low share price is currently -.
There are currently 68,386,857 shares in issue and the average daily traded volume is 0 shares. The market capitalisation of Avacta is £43,083,719.91.
22/3/2017
20:54
lantanatony: Yes the immunogenicity results are key. However,the big question is,Finncap have such poor placing power in this sector,can they support any good news? They predict a share price of around £2 later this year but can't find any real support at 65 pence! In my view Finncap are the wrong broker in this sector. If Avacta have serious technology they need a serious broker.
20/3/2017
10:59
dec2016: I come back to perspective. Of course its true that there are other compounds and ranges of compounds out there that can make money. The key questions on this bulletin board are not whether other strategies can win, but (a) whether Affimers have a niche in the global biotech marketplace and if so what might be their competitive advantage and (b) do the current management have the ability to see this through to achieving success.. achieving real commercial traction. The first of these questions is addressed head-on by two new papers on the Avacta website www.avacta.com/investors/documents entitled "Affinity Reagents: The Landscape and Affimer Technology Competitive Advantages" and "Immunogenicity Data: A Key Milestone". These address many of the issues raised by wan on this BB. They are also quite realistic. They do not make the claim that Affimers are the only game in town. Rather they seek to show that they are a powerful tool, they work, they have advantages and the potential markets are huge, so there should be ample scope for Affimers to find a very profitable niche. They also confirm, for those who are still sceptical, that the whole area of protein scaffolds has excited huge interest and indeed continues to do so. We need to note that such claims are not just backed by the opinion of the management, but by real deals in the commercial world not just with Moderna but also with Horizon as well as the support of IP Group and the support of some significant academics. In this context it should also be pointed out that Avacta, as far as I can tell uniquely amongst protein scaffold companies, are adopting a "multiple shot on goal strategy" by going not just for therapeutic markets but also for those in diagnostics and research reagents. Of course nothing is guaranteed, but it surely increases the chances of some hits on goal. That leaves the major unknown for Avacta as the quality of the management. Can they turn that theoretical competitive advantage into concrete commercial traction? Can they make sales in sufficient volume? That is the key challenge the company now faces. As an investor one has to try to forecast how that might turn out. The data available to us now to try to answer that question must include the fact they have got the backing of IP Group, and other investors in a significant rights issue, that they have taken the Affimer technology and commercialised it in new facilities and they have credible programmes under way with substantial partners in both therapeutics and diagnostics. The uncertainty is that they have not yet closed a significant commercial deal... What they have said is that they are confident the first deal(s) will be closed in 2017. It seems to me entirely possible that such deals will be closed. The resultant question for investors is therefore perhaps.. what level of revenue from such deals is necessary to justify the current 66p share price? and how likely are they to achieve that level of revenue?
25/2/2017
19:28
wan: Lentjes...Read the original announcement - "Mr Albin will invest a total amount of GBP12,500 per annum in new Avacta shares. He will purchase the shares on a quarterly basis, purchasing GBP3,125 of new shares on each of 31 March, 30 June, 30 September and 31 December. The purchase price of the shares will be the average mid-market closing share price for the five trading days immediately prior to each quarter-end. The terms pursuant to which Mr Albin will purchase his shares are fixed and he has irrevocably committed to such terms." Just to be clear though, in March Albin did not buy £3,125 worth.
19/2/2017
17:31
wan: Dec2000..."getting out of control" is an overreaction! If you go back a few pages to my post 935 you will read some good exchanges in response to me putting a decent case that Avacta has been a perennial under-performer. The chart at the top of this thread paints a thousand words! Lentjes...If you also read back a few pages it will be clear that there is little evidence of me simply criticising any positive posts. I may challenge the specifics or general thrust, but on the whole and certainly compared to some threads, this one is 'very' measured, orderly and cordial! I am ultimately on the side of the private investor, and it's just unfortunate that some investors will not like any degree of criticism. I believe that even some good news flow has the potential to bring out sellers (if any buyers emerge!) i.e. there is a queue at the exit, because the door to that exit is routinely closed by the market makers. Hence the share price performance often reflects the one step forward and two back syndrome. Management suggest that recent progress has not been recognised in the shares....it's because there are many willing sellers stupid! Investors who are sellers and who ultimately have no faith in the management or what the management state! The fact is, alternatives to antibodies have been around for a very long time with some having been established since at least 1999, but antibodies are the ones that have flourished and the ultimate commercial breakthrough in therapeutics for non-antibody alternatives has still not arrived. In non-therapeutic applications antibodies also dominate, with many non-antibody alternatives now suggesting that their offerings are superior to antibodies, yet despite these apparent advantages and being available for a very long time, again a breakthrough in non-therapeutic applications has yet to emerge. Avacta are quick to announce a collaboration, but fail to announce when a collaboration has come to nothing, leaving us to try to work it out for ourselves! Here are some excerpts from one of my recent previous posts (965) - "Anyone with the slightest thought of Affimers disrupting the antibody market will be very disappointed as Antibodies and the plethora of alternatives will almost certainly coexist, but given the wide array of existing and emerging alternatives, the non-antibody market will not be controlled or dominated by any one technology! That's not to say alternatives to antibodies will not ultimately prove successful, but it is likely to be a highly fragmented market as they all have similar attributes, albeit some may command niche markets, which may prove enough financially, but in some situations niche might not provide the level of value inflection ultimately hoped for. Although I remain open minded, in my opinion it is unlikely that Affimers will prove to be particularly superior to anything else out there, and whilst there might be room for several protein scaffolds across the range of therapeutic and non-therapeutic applications, it appears that there will be far more than just a few alternatives vying for a slice of the same business. Furthermore, several of Avacta's previous collaborations have come to nothing (and did not get a mention in the AR), does this indicate similar in terms of increasing competitive offerings, or that Affimers failed to meet expectations? One would assume that it's one or a combination of both of them." (END) Recall that Avacta dropped the development of Affimer microarrays, despite predicting imminent revenues from such. So we have heard it all before regarding imminent revenues! I very reluctantly let that go at the time (albeit I did challenged the rationale/decision), but it is yet another example of failure to deliver on the promise/strategy. Given Avacta's past history, I think we can assume that the microarrays simply did not come up expectations, which implies (along with other failed collaborations) that Affimers are perhaps not as perfect as Avacta imply. I remain of the personal opinion that unless Avacta can delivery exceptionally strong revenue growth in 2017, they are likely to need to raise further funds in 2017. Perhaps especially so, given that some are predicting that with the introduction of MiFID II in January 2018 reshaping the landscape for "independent" research, it could become an increasingly difficult market for SMEs looking to raise capital.
18/2/2017
11:58
dec2000: This thread is getting out of control. As far as I can see, there are indeed a number of scaffolds.. and some of the companies that developed them have been acquired by others, some have gone on to be valuable in their own right (eg Molecular Partners) and some have recently done potentially significant deals with others (eg Pieris). We need to keep these things in context and even in perspective. We have to remember that some significant partners have done deals with Avacta (Moderna and Memorial Sloan Kettering) OK these are subject to performance but these organisations would not even bother to start unless they thought that Affimers had promise. Then we have to remember that the biggest shareholder is IP Group and they are not fools. Far from it. Also Avacta has reported good progress with the therapeutic Tx side of the business and we have the testimonial from Ramzi. Next remember that the Scientific Advisory Board consists of some very significant indeed eminent people who would not bother if they thought Affimers were a waste of time. Finally remember that the company has generated genuine revenue in the Reagents and Diagnostics space for paid-for projects with other biotech companies and Alistair has indicated that we will see the first proper revenue for Affimer powered products in 2017. My take is that it is very frustrating that it is taking time, but this is inevitable and what we need is patience. Also remember that the big institutions are not selling.. so the fall in the share price is due to private individuals selling and this happens because of the drip of bad comments in sites such as this!!! Lets have some patience and sense ! Then we will see the share price rise not fall!
04/12/2016
09:27
wan: I note we now have the reason for the recent drop in the share price, in the form of a relatively large sell trade at 75p. I don't talk about the share price very often, but to perhaps put some perspective across regarding Avacta's share price performance, emerging U.S. biotech firms are down 39 percent this year and their European counterparts are down by 27 percent (and I appreciate that that probable doesn't make anyone feel any better). The main reason driving this under-performance, relative to the wider equity markets, is that drug pricing is weighing on investors minds and it has shifted sentiment. However, with large pharma showing strong interest in preclinical assets, it has been a good year for some companies with early stage assets to sell. Indeed, news elsewhere shows that large pharma is also very interested in alternatives to antibodies and it also continues to demonstrate their strong interest in preclinical assets - Better than ADCs? AstraZeneca bids for Bicyclic Peptides AstraZeneca has signed a deal with Bicycle Therapeutics that could exceed €1B. The foundation is bicyclic peptides, which combine the best of antibodies and small molecules. Could Bicycle Drug Conjugates (BDCs) outperform ADCs? Peptides tend to be unpopular because they’re usually less specific than antibodies, although Amcure in Germany is also relying on them to treat cancer. Although the bicyclic peptide technology hasn’t proved itself worthy in the clinic yet, AstraZeneca seems to be attracted by the myriad advantages it offers. For Bicycle Therapeutics, this agreement means an expansion into new disease areas, which were mostly restricted to oncology so far. Full story - http://labiotech.eu/bicycle-therapeutics-astrazeneca/ The AstraZeneca deal with Bicycle is interesting in terms of the development stage of Bicycle. It is also perhaps more than interesting in terms of it being about an alternative to antibodies, which we know are expensive to produce (not to mention other issues). So this brings me back to drug pricing, and it is interesting that if a peptide works in a particular application then it could be attractive because it is easy to produce and subsequently much cheaper than antibodies. It will thus be interesting to see if acquiring or partnering assets that can ultimately reduce the cost of drugs becomes a trend. If so, then Avacta could be in an even better place than some are currently assuming. My research indicates that Affimers, being proteins, have larger interaction areas, have a greater range of conformations and higher affinities than peptides, hence the range of collaborations to date. So, while Bicycle's offering has clearly caught attention (another example of British success....well done!), it's not difficult to imagine that Affimers are attracting interest beyond the already declared interest coming from affinity separation, immunoassays and lateral flow diagnostics players. I appreciate though that some investors are only interested in substance i.e. something tangible and meaningful in terms of cash, as opposed to promises. But Avacta has attracted some very interesting and talented people (including collaborations), and such individuals don't usually align themselves to technologies or small companies without very good reason. Whilst some on here are inclined to describe Avacta as a failure waiting to happen, I am far more inclined to describe Avacta as another British success waiting to happen! We should champion British companies, especially ones that could also make a significant difference to peoples lives. Staying with British; I note that whilst I was away recently a sizeable UK focused fund is being created - Battle Against Cancer joins Wellcome to be £1bn champion Battle Against Cancer Investment Trust plans to team up with Wellcome Trust and become national champion in healthcare research The £483 million company today announced a big change in direction, unveiling plans to deepen its involvement in cancer research and biotechnology investment. It will potentially more than double in size to £1 billion and will gradually wind down its investments in alternative funds. ‘The same logic has given rise to this transaction, which will create a national champion of life science investing and accelerate the achievement of our aim: to win the battle against cancer and to create great returns for our investors at the same time.’ ‘This represents a major change in strategy for Bacit,’ said Numis analyst Ewan Lovett-Turner. ‘The tie-up with Wellcome Trust is an interesting development that looks set to create a sizeable listed company to support investment in UK life sciences. Full story - http://citywire.co.uk/money/battle-against-cancer-joins-wellcome-to-be-1bn-champion/a966356 And the following also stood out - £226 million UK investment in cancer research announced 1st December Cancer Research UK has announced the largest investment to date into its network of Centres across the UK. £190 million has been committed to 13 Cancer Research UK Centres over the next five years. “I’m particularly pleased that our international panel of experts, which renewed these Centres, stated repeatedly their view that there is no other network like this, of this quality, anywhere else in the world. “This is an exciting time for cancer research. Emerging treatments like immunotherapy are radically changing the field, we are increasingly able to tailor more treatments to individual patients, and advances in technology mean we can collect and share more research data than ever before. Full story - http://www.cancerresearchuk.org/about-us/cancer-news/press-release/2016-12-01-ps226-million-uk-investment-in-cancer-research-announced
01/12/2016
10:32
dec2000: Clearly the market knows well in advance (24 hours) of us "normal shareholders" about RNS messages etc. However the drop in share price does not seem to have any fundamental support or reason. As I mentioned yesterday the drop in share price does not even seem to be linked to any significant share sale. The strategic update just released confirms everything we know about the company. There are no surprises. I e mailed Alastair Smith and whilst he cannot comment on share movements specifically, he expressed his "frustration" at yesterday's sudden movement and confirmed the steady progress of the company. Overall I believe the best conclusion is that this is an attempt to manipulate the share price (which often happens for small companies) and the right response is to sit tight and even use it as a buying opportunity
30/11/2016
18:41
dec2000: Yet Finncap yesterday placed a value on AVACTA of 200p in 12 months! Avacta Group PLC (LON:AVCT) Issued With ‘CorporateR17; Rating At FinnCap By Warren Smith / in UK Broker Ratings / on Wednesday, 30 Nov 2016 02:02 PM / 0 Comments Following an update released by analysts at finnCap on Tuesday the broker has now set a ‘CorporateR17; rating on shares of Avacta Group PLC (LON:AVCT) with a price target of 200. On Tuesday finnCap reiterated its target for shares of Avacta Group PLC as ‘CorporateR17; recommending a target price of 200 for investors; potentially meaning there is an increase of 129.75% from Avacta Group PLC’s share price of 87.05. Avacta Group PLC has 68,287,000 shares currently held by shareholders which currently trade around the 87.05 mark which totals Avacta Group PLC’s market capitalisation to 59.44M GBP. 12 Month Share Chart For Avacta Group PLC LON:AVCT In the duration of 12 months Avacta Group PLC’s share price has increased by 0% to 87.05 from 0.00. The business has a 50 day moving average of 89.99 and a 200 day moving average of 95.94 whilst the 52 week high shares of Avacta Group PLC have reached is 134.5 and the 52 week low is 83.02. Avacta Group plc is the developer of Affimer bio therapeutics and research reagents. The Company’s segments include Animal Health, which provides tools and contract services to assist diagnosis of conditions in animals to enable treatment for veterinarians, and Life Sciences, which provides reagents and arrays for diagnostics, drug and biomarker discovery in biotech research and development. The Company’s in-house programs include Oncology, which is engaged in developing combination therapies combining multiple immune checkpoint inhibitors by making bi- and tri-specific Affimer constructs, and Blood clotting disorders, which allows Affimer therapeutics to generate the modulate blood clot formation with the potential for anti-thrombotic, as well as wound healing therapies. It focuses on its Affimer technology, which is an engineered alternative to antibodies that has application in Life Sciences for diagnostics, therapeutics and general research and develoPment
30/11/2016
12:38
dec2000: if you look at the share trades it seems to have continued as normal then the share price fell a few p even though only a small number of trades was going through and then a sell order came through for 30000.. though the share price was dropping by then.. then subsequent partial rebound... either someone knows something we don't eg failure to sign a contract or even a hiccup with the Moderna deal or else its just a random fluctuation... no news on web site
28/9/2016
10:28
lantanatony: Wan,I know you are trying to be helpful and I am impressed with your grasp of the subject. However,the share price continues to fall and I still believe it will until we see some revenue attached deals from substantial Bio-Phama companies. Like you I feel Avacta will make but I could be a while. Meanwhile,its up to the Avacta Board to add shareholder value. However,this impressive Board needs to do more to support the share price.Otherwise Henderson and others will lose patience. They invested at around 1.20 and must be a little disappointed ?
Avacta share price data is direct from the London Stock Exchange
Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:42 V: D:20170325 21:50:46